HC Wainwright Reiterates $2.00 Price Target for Advaxis (ADXS)

HC Wainwright set a $2.00 price target on Advaxis (NASDAQ:ADXS) in a research note published on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, ValuEngine raised shares of Advaxis from a hold rating to a buy rating in a research note on Thursday, November 1st.

ADXS traded down $0.03 on Tuesday, reaching $0.55. The stock had a trading volume of 283,998 shares, compared to its average volume of 644,991. Advaxis has a 12-month low of $0.47 and a 12-month high of $3.58. The stock has a market capitalization of $30.81 million, a price-to-earnings ratio of -0.24 and a beta of 2.52.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Monday, September 10th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The firm had revenue of $1.13 million during the quarter, compared to analysts’ expectations of $1.85 million. Advaxis had a negative net margin of 1,062.68% and a negative return on equity of 165.23%. On average, analysts predict that Advaxis will post -1.09 earnings per share for the current year.

In related news, Director Roni Appel bought 33,333 shares of the business’s stock in a transaction dated Tuesday, September 11th. The stock was acquired at an average price of $1.20 per share, with a total value of $39,999.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.21% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in ADXS. LMR Partners LLP purchased a new stake in shares of Advaxis during the second quarter worth about $171,000. Franklin Street Advisors Inc. NC acquired a new position in Advaxis during the second quarter worth about $190,000. Paloma Partners Management Co acquired a new position in Advaxis during the second quarter worth about $265,000. Finally, BlackRock Inc. boosted its position in Advaxis by 28.2% during the first quarter. BlackRock Inc. now owns 2,925,417 shares of the biotechnology company’s stock worth $4,943,000 after acquiring an additional 644,201 shares during the last quarter. 21.32% of the stock is owned by institutional investors and hedge funds.

About Advaxis

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Recommended Story: Relative Strength Index

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply